IBC Meeting Minutes
Cleveland Clinic Main Campus

Date:	**Location:**
May 12th, 2026	Zoom

IBC Member Attendance:

☐ Ahern, Philip	☐ Bukavina, Laura	☒ DiDonato, Joseph
☒ Dragan, Amanda (BSO)	☐ Hajjar, Adeline	☐ Heemers, Hannelore
☐ Kerr, Travis	☒ Lindner, Daniel	☒ McDonald, Christine (IBC Chair)
☒ Mortimer, Joanne	☒ Urban Molly	☒ Such, Kimberly

Guests: Anthony Santilli, Jennifer Veillette*, Nikki Meyer*, Anna Rietsch*, Anna Simko*, Sara Tavakoli**, Dylan Chamber***

** Cleveland Clinic*
*** Cleveland Clinic Florida Research & Innovation Center*

Call To Order:	**Adjourn:**
3:01 PM	3:49 PM

I. Review of April 29th, 2026 Meeting Minutes

Committee Comments:
None

Motion Approval:	**For:**	**Against:**	**Abstain:**
Approved	7	0	0

II. Administrative Business

a. Floor plans for new laboratory spaces were presented to the IBC.

III. Non-Clinical Research:

a. Amendments

Basic Research Amendment #1	**Protocol ID:** IBC 2106	**PI:** Scheraga	**Biosafety Level:** BSL-1, BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-4-b

Project Titles:

TRPV4 Mediates the Bacterial Pneumonia and Viral Response; Mechanisms of Lung Injury after Infection

Associated Grant Numbers:
R01HL155064

Summary of Approved Items:
Acquisition of wt and recombinant bacteria, Adeno-Associated Viral particles (AAV), non-recombinant Influenza Virus; administration *in vivo*; Human-derived materials.

Requested Additions/Changes:

- Replication defective adeno-associated viral particles
- Gene targets
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☐ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☒ Signaling ☐ Antimicrobial ☒ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☒ Cell Metabolism ☒ Other

Species of Recombinant Genes to be Expressed:
☐ N/A ☒ Human ☒ Murine ☒ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- Remove locations that are not relevant to this protocol
- Confirm removal of previously approved areas
- For *in vivo* procedures, if no location specific equipment is needed, they should still be performed in prior approved spaces
- For procedures occurring in new locations, update protocol to ensure they are transported to the appropriate corresponding rooms
    - A guidance document will be provided for moving *in vivo* experiments to and from the new locations. Please refer to this guidance in the protocol.
- Please clarify rooms for indicated *in vivo* experiments to match prior communications
- Minor administrative revisions and updates

Motion Approval:	**For:**	**Against:**	**Abstain:**	**Recuse:**	**Not Present:**
Approved w/ Administrative Revisions	6	0	0	1	0

Basic Research Amendment #2	Protocol ID: IBC 2103	PI: Hajjar	Biosafety Level: BSL-1, BSL-2, ABSL-2	NIH Cat.: III-D-1-a, III-D-4-b

Project Titles:
Microbiota and cystic fibrosis

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Propagation of recombinant and non-recombinant bacterial strains; Administration *in vivo*.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	Facilities, Procedures, and Safety Practices Reviewed: ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	Handler Training (Y/N): ☒ Yes ☐ No

Discussion/Required Modifications:

- Update indicated room to only BSL-1 work
- Remove *in vivo* work from indicate space
- For the indicated experiments, please outline the specific rooms used from the list of approved locations
- Indicate new location for ABSL-2 procedures

Motion Approval: Approved w/ Administrative Revisions	For: 7	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0

Basic Research Amendment #3	Protocol ID: IBC 2205	PI: Xie	Biosafety Level: BSL-1, BSL-2, ABSL-2	NIH Cat.: III-D-1-a, III-D-3-a, III-D-4-b, III-E

Project Titles:

Organization, Dynamics and Mechanisms of Extrachromosomal DNA in Human Cancer; Study the regulation of extrachromosomal DNA in human glioblastoma

Associated Grant Numbers:
R01 NS145466-01, R21 NS144792-01

Summary of Approved Items:
Generation of replication defective lentiviral and adeno-associated viral (AAV) particles, transduction of tissue culture cells, administration *in vivo*; Transfection of tissue culture cells, administration *in vivo*; Human-derived materials.

Requested Additions/Changes:

- Human tissue culture cell lines
- Mammalian expression vectors
- Gene targets and genes for editing
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☐ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☒ Structural ☒ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☒ Other

Species of Recombinant Genes to be Expressed:
☐ N/A ☒ Human ☐ Murine ☒ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- Update tissue culture cell inventory to indicate that specified cell line is recombinant

Motion Approval: Approved w/ Administrative Revisions	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #4	**Protocol ID:** IBC 2022	**PI:** Jung	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-3-a, III-D-4-b, III-E

Project Titles:
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Responses against KSHV Infection

Associated Grant Numbers:
R01DE028521, R01CA251275, R01AI151013, R01AI181758-01A1, R01CA295170-01

Summary of Approved Items:
Generation of replication deficient lentiviral particles, transduction of tissue culture cells; Propagation of Hepatitis B Virus (HBV) particles and recombinant modified and WT Orf Virus (ORFV) and Kaposi's sarcoma-associated herpes virus (KSHV) particles, and infection of tissue culture cells; acquisition of WT and recombinant modified cell lines that are positive for KSHV, Epstein Barr Virus (EBV); Administration of cells *in vivo*. Processing of human blood positive for EBV and Cytomegalovirus (CMV), Non K-12 E.coli; Human-derived material.

Requested Additions/Changes:

- Mammalian expression plasmid
- Gene targets
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☐ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☒ Other

Species of Recombinant Genes to be Expressed:
☐ N/A ☒ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #5	**Protocol ID:** IBC 1903	**PI:** Messer	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-4-b, III-E

Project Titles:
Host-microbe interactions at mucosal barriers

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:

Growth of recombinant and non-recombinant bacteria and fungi strains and infection of tissue culture cells; administration of bacteria *in vivo*; Human- derived materials.

Requested Additions/Changes:

- Wild type *Candida auris*,
- Human cell lines
- Room additions

Function/Nature of Recombinant Genes to be Expressed:

☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:

☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- For *in vivo* experiments, add indicated language for disinfectants and/or contact times that deviate from facility specific protocols

Motion Approval: **Approved w/ Administrative Revisions**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #6	**Protocol ID:** IBC 1925	**PI:** Stappenbeck	**Biosafety Level:** BSL-1, BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-3-a, III-D-4-b

Project Titles:
Signals that control Inflammatory Bowel Disease- Replication defective retrovirus and lentivirus

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Generation of replication defective lentivirus and retrovirus, transduction of tissue culture cells; Acquisition of commercially available adenovirus and transduction of tissue culture cells; administration of lentiviral transduced cells *in vivo*; Human-derived material.

Requested Additions/Changes:

- Acquisition of diphtheria toxin for use in-vitro
- Replication defective lentiviral particles
- Gene targets
- Room additions

Function/Nature of Recombinant Genes to be Expressed:

☐ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☒ Other

Species of Recombinant Genes to be Expressed:

☐ N/A ☒ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #7	**Protocol ID:** IBC 2047	**PI:** Wu	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-2-a, III-D-3-a

Project Titles:
Elucidating the mechanisms of intrinsic stem cell resistance to virus infection

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Generation of replication defective lentivirus and transduction of tissue culture cells

Requested Additions/Changes:

- Gene targets and genes for editing
- Administration of transduced cells *in vivo*
- Room additions

Function/Nature of Recombinant Genes to be Expressed:

☐ N/A ☒ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☒ Cell Metabolism ☒ Other

Species of Recombinant Genes to be Expressed:
☐ N/A ☒ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- Specified rooms were updated to BSL-2.

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #8	**Protocol ID:** IBC 2414	**PI:** Wu	**Biosafety Level:** BSL-1, BSL-2	**NIH Cat.:** III-D-1-a, III-D-2-a, III-D-3-a

Project Titles:
Investigating the complex interactions between various neuronal cells and neurotropic viruses

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Generation of replication deficient lentiviral particles; transduction of tissue culture cells; generation of recombinant Venezuelan equine encephalitis virus (VEEV) (vaccine strain) and yellow fever virus (YFV) (vaccine strain), infection of tissue culture cells; human-derived materials.

Requested Additions/Changes:
- Room Additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:**☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No
Discussion/Required Modifications: • No modifications requested	

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #9	**Protocol ID:** IBC 2222	**PI:** Stacy	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-4-b

Project Titles:
Oral microbiota-host interactions in periodontitis

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Generation and propagation of recombinant and non-recombinant modified bacteria; co-culture in-vitro, Gingiva-on-a-Chip; administration of bacteria *in vivo*; Human-derived material.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:**☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No
Discussion/Required Modifications: • Please remove locations that don't involve IBC related procedures	

Motion Approval:	**For:**	**Against:**	**Abstain:**	**Recuse:**	**Not Present:**

Approved w/ Administrative Revisions	7	0	0	0	0

Basic Research Amendment #10	**Protocol ID:** IBC 2026	**PI:** Jung	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b, III-E

Project Titles:
Identifying host determinants involved in immunoregulation

Associated Grant Numbers:
R01AI140705, R01AI152190, R01AI171201

Summary of Approved Items:
Generation of replication defective adeno-associated viral particles, transduction of tissue culture cells, and administration *in vivo*. Generation of replication defective lentiviral particles and transduction of tissue culture cells. Acquisition of SARS-CoV-2 strains, generation of recombinant Hepatitis B Virus, human Respiratory Syncytial Virus (RSV), SARS-CoV-2 strains and Mumps Virus; administration of Hepatitis B Virus, SARS-CoV-2 *in vivo*. Acquisition of Parainfluenza Type III (PIV3), Human Metapneumonia (hMPV) virus. Administration of plasmid infected cells expressing HBV *in vivo*. Generation and administration of mRNA vaccine *in vivo*. Generation of protein vaccine and administration *in vivo*; Protozoan Leishmania tarentolae protein expression system; Non-K12 E. coli; Human-derived materials

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- Update Room List to indicate locations of *in vivo* procedures
- For procedures occurring in new locations, update protocol to ensure they are transported to the appropriate corresponding rooms.

○ A guidance document will be provided for moving in vivo experiments to and from the new locations. Please refer to this guidance in the protocol. • Administrative revisions and updates

Motion Approval: **Approved w/ Administrative Revisions**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #11	**Protocol ID:** IBC 2201	**PI:** Vachharajani	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-4-b

Project Titles:
Sepsis immune dysfunction & post-sepsis infections

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Acquisition and propagation of fungus and recombinant and non-recombinant bacteria, co-culture with cell lines and administration of bacteria and fungus *in vivo*; Human-derived material.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- Update *in vivo* description and Room List to indicate locations of *in vivo* procedures
- For *in vivo* procedures, if no location specific equipment is needed, they should still be performed in prior approved spaces
- For procedures occurring in new locations, update protocol to ensure they are transported to the appropriate corresponding rooms

○ A guidance document will be provided for moving in vivo experiments to and from the new locations. Please refer to this guidance in the protocol.

Motion Approval: Approved w/ Administrative Revisions	For: 6	Against: 0	Abstain: 0	Recuse: 1	Not Present: 0

Basic Research Amendment #12	Protocol ID: IBC 2602	PI: Vachharajani	Biosafety Level: BSL-1, BSL-2	NIH Cat.: III-D-1-a, III-D-3-a

Project Titles:
Viral Transduction of mammalian cells in sepsis

Associated Grant Numbers:
R01GM99807, R01AI153085

Summary of Approved Items:
Generation of replication defective lentiviral and adeno-associated viral (AAV) particles, transduction of tissue culture cells; Human-derived materials.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion:	Facilities, Procedures, and Safety Practices Reviewed:
☒ Yes ☐ No	☒ Yes ☐ No
PI/Supervisor Training (Y/N):	**Handler Training (Y/N):**
☒ Yes ☐ No	☒ Yes ☐ No

Discussion/Required Modifications:

- Minor administrative revisions and updates

Motion Approval: Approved w/ Administrative Revisions	For: 7	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0

Basic Research Amendment #13	Protocol ID: IBC 2044	PI: Miller	Biosafety Level:	NIH Cat.: III-D-1-a

			BSL-2	

Project Titles:
The Role of the Urinary Microbiome on BCG Response in Non-Muscle Invasive Bladder Cancer

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Propagation of non-recombinant bacteria, infection of cells in culture including co-culturing; transformation of an attenuated strain of *Myobacterium bovis* and infection of cells in culture. Human-derived materials.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #14	**Protocol ID:** IBC 0510	**PI:** O'Connor	**Biosafety Level:** BSL-2	**NIH Cat.:** III-D-1-a, III-D-3-a

Project Titles:
Antiviral actions of interferon response

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:

Propagation of Encephalomyocarditis Virus (EMCV), Sendai Virus (SeV), Influenza A, Respiratory Syncytial Virus (RSV), Human Herpes Simplex Virus 1 (HSV-1), Human Adenovirus 5, and Murine Hepatitis Virus; Infection of tissue culture cells; Human derived materials.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:

☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:

☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #15	**Protocol ID:** IBC 1628	**PI:** O'Connor	**Biosafety Level:** BSL-2	**NIH Cat.:** III-D-1-a, III-D-2-a, III-D-3-a

Project Titles:
Deciphering mechanisms underlying glioblastoma stem cell expansion

Associated Grant Numbers:
R01AI150931, R01AI153348

Summary of Approved Items:
Generation of replication defective lentivirus and retrovirus particles and transduction of tissue culture cells; human-derived material

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:

☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #16	**Protocol ID:** IBC 1629	**PI:** O'Connor	**Biosafety Level:** BSL-2	**NIH Cat.:** III-D-1-a, III-D-3-a

Project Titles:
Mechanisms of HCMV infection and pathogenesis

Associated Grant Numbers:
R01AI150931, R01AI153348

Summary of Approved Items:
Acquisition and generation of WT and recombinant modified human Cytomegalovirus (HCMV) and transduction of tissue culture cells; Acquisition of potentially infectious or with known infectious human material; human-derived material.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No
Discussion/Required Modifications: • No modifications requested	

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #17	**Protocol ID:** IBC 2021	**PI:** Jung	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-4-b

Project Titles:
Molecular mechanisms underlying the immunopathogenesis of vector-borne viruses

Associated Grant Numbers:
U19AI171443

Summary of Approved Items:
Propagation of non-recombinant Zika Virus, Dengue Virus, Sindbis Virus, Recombinant modified Venezuelan Equine Encephalitis Virus (attenuated), & Chikungunya Virus (attenuated), infection of cells in culture. Administration of Zika Virus, Dengue Virus, Sindbis Virus, & Venezuelan Equine Encephalitis Virus *in vivo*. Acquisition of Sendai Virus, infection of cells in culture; Human-derived material.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No
Discussion/Required Modifications: • No modifications requested	

Motion Approval: Approved	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #18	**Protocol ID:** IBC 2023	**PI:** Jung	**Biosafety Level:** BSL2, ABSL2	**NIH Cat.:** III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b, III-E

Project Titles:
Identifying viral determinants involve in viral-host interactions using infectious clones

Associated Grant Numbers:
R01 AI140705, R01 AI52190, R01AI151013

Summary of Approved Items:
Propagation of non-recombinant Murine Coronavirus, Human Coronavirus, La Crosse Virus, Utinga Virus, Simbu Virus, Manzanilla Virus, Buttonwillow Virus, Ingwavuma Virus, Jamestown Canyon, Cache Valley Viruses rodent herpesvirus Peru E and L virus, Oropouche Virus and Uukuniemi Virus. Propagation of recombinant Zika virus, Kaposi's Sarcoma associated herpesvirus, Murine Gammaherpesvirus 68 (MuHV-68), Measles virus, Mumps virus, Oropouche Virus (OROV), and Herpesvirus; Generation of replication competent Retroviral particles; Handling of Measles, Mumps, HRTV, SFTSV Viral Vector vaccines; Generation of mRNA vaccines; Administration of all agents *in vivo*. Acquisition and processing of Epstein – Barr virus positive samples, Non K-12 E. coli; Human-derived material.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval: Approved	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #19	**Protocol ID:** IBC 2025	**PI:** Jung	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-3-a, III-D-4-b

Project Titles:
Discovery of novel therapeutic strategies against airborne viruses

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Propagation of Influenza A virus (H1N1), Enterovirus, human Parainfluenza Virus 4a, Adenovirus 10, human Metapneumovirus, human Rhinovirus (HRV-16), Respiratory syncytial virus (RSV), non-recombinant and recombinant modified Measles Virus; Transduction of cells in culture, administration *in vivo*. Generation of replication deficient lentiviral particles and transduction of tissue culture cells; acquisition and generation of adeno-associated viral particles and administration *in vivo*; Human-derived materials.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval: Approved	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #20	Protocol ID: IBC 2027	PI: Jung	Biosafety Level: BSL-2, ABSL-2	NIH Cat.: III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b, III-E

Project Titles:
Molecular mechanisms of virus-mediated cell death

Associated Grant Numbers:
R35CA200422-05

Summary of Approved Items:
Propagation of Herpes Simplex virus-1 (HSV-1), Vesicular stomatitis virus (VSV), Bunyamwera virus and Influenzas A Virus; non-recombinant and recombinant modified Human Cytomegalovirus (HCMV), Murine Cytomegalovirus, Murid beta herpesvirus 1 (MCMV), Vaccinia virus (VACV); Generation of replication defective lentiviral particles, transduction of tissue culture cells.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	Facilities, Procedures, and Safety Practices Reviewed: ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	Handler Training (Y/N): ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval: Approved	For: 7	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0

Basic Research Amendment #21	Protocol ID: IBC 2113	PI: Jung	Biosafety Level: BSL-2	NIH Cat.: III-D-1-a, III-D-3-a

Project Titles:
Modeling liver diseases using a human pluripotent stem cell derived-multicellular platform

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Generation of replication defective lentivirus viral particles and transduction of tissue culture cells; propagation of recombinant hepatitis B virus, herpes simplex virus – 1 and acquisition of recombinant Kaposi Sarcoma Associated Herpesvirus (KSHV) and infection of tissue culture cells; Human-derived materials.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- Room additions

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #22	**Protocol ID:** IBC 2311	**PI:** Jung	**Biosafety Level:** BSL-1	**NIH Cat.:** III-D-2-a, III-E-1

Project Titles:
Identifying the role of viral intergenic regions in HRTV, SFTSV, and POWV protein transcription

Associated Grant Numbers:
R01 AI152190

Summary of Approved Items:
Handling of DNA from a Risk Group 3 organisms, plasmid transfection in tissue culture cells, transformation of K12 E. coli

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:

☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:

☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #23	**Protocol ID:** IBC 2315	**PI:** Jung	**Biosafety Level:** BSL-1, BSL-2, BSL-3, ABSL-3	**NIH Cat.:** III-D-1-a, III-D-2-a, III-D-3-a, III-3-D-b, III-D-4-b

Project Titles:

Identifying effective drug targets against RNA viruses

Associated Grant Numbers:

R01 AI52190, R01 AI140705, R01 AI171201

Summary of Approved Items:

Propagation of non-recombinant SARS-CoV-2 isolates, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Powassan virus, Hantaan virus & Heartland virus; propagation of recombinant-modified Heartland virus, Severe fever with thrombocytopenia syndrome virus (SFTSV), SARS-CoV-2, SARS-CoV-2 isolates, SARS-CoV-2 mouse adapted. Infection of cell lines: Co-infection with non-recombinant Oropouche Virus, La Crosse Virus, Utinga Virus, Simbu Virus, Manzanilla Virus, Lone Star Virus, Bunyamwera Virus and recombinant Uukuniemi virus; Acquisition of adenovirus and administration *in vivo*; Administration of recombinant and non-recombinant viruses *in vivo*; Human-derived materials.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #24	**Protocol ID:** IBC 1810	**PI:** Clasen	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-4-b

Project Titles:
Identification and in vitro & in vivo characterization of bacterial biosynthetic gene clusters

Associated Grant Numbers:
R01AI153173

Summary of Approved Items:
Acquisition of various human and rodent-derived material, microbial isolates; generation and culturing of various recombinant and non-recombinant modified bacteria; co-culture in tissue culture cells; and administration *in vivo*; Human-derived material.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No
Discussion/Required Modifications: • Identify rooms used for indicated procedures from the list of approved spaces	

Motion Approval:	**For:**	**Against:**	**Abstain:**	**Recuse:**	**Not Present:**
Approved w/ Administrative Revisions	7	0	0	0	0

Basic Research Amendment #25	**Protocol ID:** IBC 1829	**PI:** Brown	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-4-b, III-F-2, III-F-8

Project Titles:
The Role of Bacterial Choline Metabolism in Host Stress Response

Associated Grant Numbers:
R01DK120679, P01HL147823

Summary of Approved Items:
Growth of recombinant and non-recombinant bacteria and fungi and administration *in vivo*

Requested Additions/Changes:
- Room Additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No
Discussion/Required Modifications: • No modifications requested	

Motion Approval:	**For:**	**Against:**	**Abstain:**	**Recuse:**	**Not Present:**
Approved	7	0	0	0	0

Basic Research Amendment #26	Protocol ID: IBC 2307	PI: Brown	Biosafety Level: BSL-1, ABSL-1	NIH Cat.: III-D-4-b

Project Titles:
The Role of the TMA-FMO3-TMAO pathway in nutrient sensing and diet-related diseases

Associated Grant Numbers:
P01HL147823

Summary of Approved Items:
Acquisition of replication defective adeno-associated virus particles, administration *in vivo*.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion:	Facilities, Procedures, and Safety Practices Reviewed:
☒ Yes ☐ No	☒ Yes ☐ No
PI/Supervisor Training (Y/N):	**Handler Training (Y/N):**
☒ Yes ☐ No	☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: Approved	For:	Against:	Abstain:	Recuse:	Not Present:
	7	0	0	0	0

Basic Research Amendment #27	Protocol ID: IBC 2313	PI: Brown	Biosafety Level: BSL-2, ABSL-2	NIH Cat.: III-D-4-b

Project Titles:
The Role of Abnormal Lipid Metabolism in Chronic Disease

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Generation of replication defective retroviral particles and acquisition of replication defective adeno-associated viral (AAV) particles; administration *in vivo*; Human derived materials.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #28	**Protocol ID:** IBC 1106	**PI:** Longworth	**Biosafety Level:** BSL-1	**NIH Cat.:** III-D-4

Project Titles:
Transcriptional Regulation by Condensin II/CAP-D3

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Plasmids in arthropods (Drosophila melanogaster)

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism

☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #29	**Protocol ID:** IBC 1303	**PI:** Longworth	**Biosafety Level:** BSL-1, BSL-2	**NIH Cat.:** III-D-1-a, III-D-3-a

Project Titles:
Condensin mediated genome organization and transcriptional regulation

Associated Grant Numbers:
R01 GM147138-02

Summary of Approved Items:
Generation of replication defective lentivirus particles and transduction of tissue culture cells; human derived material

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications: • No modifications requested					
Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #30	**Protocol ID:** IBC 0710	**PI:** Gupta	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-3-a, III-D-4-b

Project Titles:
Spatial organization and regulation of B cell activation; Development of novel cancer therapeutics

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Generation of replication defective lentiviral particles, transduction of tissue culture cells, administration of transduced cells *in vivo*; human-derived material.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications: • No modifications requested					
Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #31	Protocol ID: IBC 2031	PI: Gupta	Biosafety Level: BSL-2	NIH Cat.: III-D-1-a

Project Titles:
Biospecimens from CAR T cell treated patients

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Molecular analysis of banked blood and saliva samples from patients receiving recombinant modified CAR-T cell therapy; Human-derived materials.

Requested Additions/Changes:

- Room Additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	Facilities, Procedures, and Safety Practices Reviewed: ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	Handler Training (Y/N): ☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: Approved	For: 7	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0

Basic Research Amendment #32	Protocol ID: IBC 1806	PI: Ahern	Biosafety Level: BSL-1, BSL-2, ABSL-1, ABSL-2, Toxin	NIH Cat.: III-D-1-a, III-D-4-b

Project Titles:
Gut microbiome modulation of immune function in health and disease

Associated Grant Numbers:
R01DK126772, R01AI18138

Summary of Approved Items:
Generation and culturing of various recombinant modified bacteria and growth of non-recombinant modified bacteria; administration *in vivo*; Isolation of various human and rodent-derived material and microbial isolates; Administration of recombinant tissue culture cell lines *in vivo*; Administration of diphtheria, cholera, and pertussis toxins *in vivo*.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- No modification requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #33	**Protocol ID:** IBC 2107	**PI:** Scheraga	**Biosafety Level:** BSL-1, BSL-2	**NIH Cat.:** III-D-1-a, III-D-3-a

Project Titles:
Molecular Mechanisms of Lung Injury

Associated Grant Numbers:
R01HL155064

Summary of Approved Items:
Generation of replication defective lentiviral, adenoviral and adeno-associated viral (AAV) particles, propagation of Influenza Virus and recombinant and non-recombinant bacteria, infection of tissue culture cells; Human-derived materials.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- Approval contingent on identifying proper area for indicated experiment

Motion Approval: **Approved w/ Contingency**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #34	**Protocol ID:** IBC 1926	**PI:** Stappenbeck	**Biosafety Level:** BS-L2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-4-b

Project Titles:
Cellular and Molecular Mediators of Intestinal Epithelial Stem Cell Responses to Injury

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Isolation and growth of recombinant and non-recombinant bacterial strains, co-culture with tissue culture cells; administration of bacteria *in vivo*, treatment of tissue culture cells with bacterial isolate; Acquisition of cholera, diphtheria and Clostridium Difficile A & B toxin and administration *in vivo*; Human-derived materials.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No			**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No		
PI/Supervisor Training (Y/N): ☒ Yes ☐ No			**Handler Training (Y/N):** ☒ Yes ☐ No		
Discussion/Required Modifications: • No modifications requested					
Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #35	**Protocol ID:** IBC 2039	**PI:** Stappenbeck	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-4-b

Project Titles:
Virus in the gut and control of Inflammatory Bowel Disease

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Acquisition of Simian Rotavirus and Murine Rotavirus, recombinant and none-recombinant modified vesicular stomatitis Indiana Virus, transduction of tissue culture cells, administration *in vivo*.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No
Discussion/Required Modifications: • No modifications requested	

Motion Approval: Approved	For: 7	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0

Basic Research Amendment #36	Protocol ID: IBC 2040	PI: Stappenbeck	Biosafety Level: BSL-1, BSL-2, ABSL-2	NIH Cat.: III-D-1-a, III-D-4-b

Project Titles:
Shaping immune response by select members of the mycobiome

Associated Grant Numbers:
R01-AI168411

Summary of Approved Items:
Acquisition and propagation of WT bacteria and yeast, generation of recombinant modified yeast strains, infection of cell lines, and administration *in vivo*; Generation of replication defective lentiviral particles, transduction of tissue culture cells, administration *in vivo*; Human-derived material.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	Facilities, Procedures, and Safety Practices Reviewed: ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	Handler Training (Y/N): ☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: Approved	For: 7	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0

Basic Research Amendment #37	Protocol ID: IBC 2101	PI: Wu	Biosafety Level:	NIH Cat.:

			BSL-2, ABSL2	III-D-1-a, III-D-3-a, III-D-4-b

Project Titles:
Modeling liver diseases using a human pluripotent stem cell derived-multicellular platform

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Generation of adeno-associated virus (AAV) and administration *in vivo*; Generation of replication defective lentivirus particles, propagation of recombinant modified Hepatitis B Virus, Hepatitis C Virus and Hepatitis E Virus and transduction of tissue culture cells, co-infection of viruses *in-vitro*; Acquisition of Norwegian Rat Hepatitis Virus and administration *in vivo*; Acquisition of transgenic *in vivo* model expressing full genome of HBV; Human-derived materials.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval:	**For:**	**Against:**	**Abstain:**	**Recuse:**	**Not Present:**
Approved	7	0	0	0	0

Basic Research Amendment #38	**Protocol ID:** IBC 2403	**PI:** Wang	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** III-D-1-a, III-D-3-a, III-D-4-b

Project Titles:
Evaluation of cytokine signaling in inflammatory diseases using lentivirus

Associated Grant Numbers:

R56 HL160639, R01 HL166544

Summary of Approved Items:
Generation of replication defective lentivirus particles, transduction of tissue culture cells; human-derived materials.

Requested Additions/Changes:
- Room Additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

b. Amendments Not Applicable to NIH Guidelines:

Basic Research Amendment #39	**Protocol ID:** IBC 2030	**PI:** Jung	**Biosafety Level:** BSL-2+	**NIH Cat.:** N/A

Project Titles:
Immunoprofiling of COVID-19 clinical specimens

Associated Grant Numbers:
R01 AI140705

Summary of Approved Items:
Acquisition and analysis of SARS-CoV-2 positive clinical specimens; Human-derived material

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #40	**Protocol ID:** IBC 2102	**PI:** Cresci	**Biosafety Level:** BSL-1, ABSL-1	**NIH Cat.:** N/A

Project Titles:
Probiotics, prebiotics, symbiotic and gut microbiota fermentation byproducts on gut-organ injury

Associated Grant Numbers:
R01AA028043

Summary of Approved Items:
Propagation and administration of non-recombinant RG1 bacteria *in vivo*.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- Add all rooms described in stepwise section to the room list
- For procedures occurring in new locations, update protocol to ensure they are transported to the appropriate corresponding rooms
    - A guidance document will be provided for moving in vivo experiments to and from the new locations. Please refer to this guidance in the protocol.

Motion Approval: Approved w/ Administrative Revisions	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #41	**Protocol ID:** IBC 1833	**PI:** Miller	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** N/A

Project Titles:
Elucidating the mechanisms of the oxalate-degrading microbial network

Associated Grant Numbers:
R01 DK121689-01A1

Summary of Approved Items:
Generation and culturing of various non-recombinant bacteria; various human and rodent-derived material; administration *in vivo*; Human-derived material.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

• No modifications requested					
Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #42	**Protocol ID:** IBC 0508	**PI:** O'Connor	**Biosafety Level:** BSL-2	**NIH Cat.:** N/A

Project Titles:
Antiviral actions of interferon response

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Propagation of Encephalomyocarditis Virus (EMCV), Sendai Virus (SeV), Influenza A, Respiratory Syncytial Virus (RSV), Human Herpes Simplex Virus 1 (HSV-1), Human Adenovirus 5, and Murine Hepatitis Virus; Infection of tissue culture cells; Human derived materials.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #43	Protocol ID: IBC 1705	PI: Cresci	Biosafety Level: BSL-1, Toxin	NIH Cat.: N/A

Project Titles:
Involvement of G-protein coupled receptors in cell signaling, inflammation and immune function in intestinal epithelial cells

Associated Grant Numbers:
R01RAA028043A

Summary of Approved Items:
Pertussis toxin to tissue culture cells; Human-derived materials.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	Facilities, Procedures, and Safety Practices Reviewed: ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	Handler Training (Y/N): ☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: Approved	For: 7	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0

Basic Research Amendment #44	Protocol ID: IBC 2407	PI: Cresci	Biosafety Level: ABSL-1, Toxin	NIH Cat.: N/A

Project Titles:
Investigation of ethanol exposure on intestinal health *in vivo*

Associated Grant Numbers:
R01AA028043

Summary of Approved Items:

Administration of diphtheria toxin *in vivo*

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:

☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:

☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- Add indicated room to room list and stepwise sections

Motion Approval: **Approved w/ Administrative Revisions**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #45	**Protocol ID:** IBC 1828	**PI:** Brown	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** N/A

Project Titles:
The Role of Bacterial Choline Metabolism in Host Stress Response

Associated Grant Numbers:
R01DK120679, P01HL147823

Summary of Approved Items:
Administration of human fecal and human oral plaque material *in vivo*; Process non-human primates samples for downstream analysis.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:

☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #46	**Protocol ID:** IBC 1816	**PI:** Gupta	**Biosafety Level:** BSL-2, ABSL-1	**NIH Cat.:** N/A

Project Titles:
B cell immune response to influenza; Regulation of B cell function

Associated Grant Numbers:
AI172916

Summary of Approved Items:
Acquisition of Influenza A viral particles, UV-inactivation of viral particles and administration of inactivated viral particles *in vivo*.

Requested Additions/Changes:
- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- **No modifications requested**

Motion Approval: Approved	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #47	**Protocol ID:** IBC 2104	**PI:** Stappenbeck	**Biosafety Level:** BSL-2, ABSL-2	**NIH Cat.:** N/A

Project Titles:
Bacteria in the gut and control of Inflammatory Bowel Disease

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Propagation of non-recombinant bacteria, infection of tissue culture cells and administration of bacteria *in vivo*.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- No modifications requested

Motion Approval: Approved	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #48	**Protocol ID:** IBC 2114	**PI:** Vachharajani	**Biosafety Level:** BSL-2	**NIH Cat.:** N/A

Project Titles:

Immune response in sepsis

Associated Grant Numbers:
R01GM99807, 5R01AI153085

Summary of Approved Items:
Acquisition of samples from healthy and septic patients, process cells for analysis; Human-derived materials.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:

- **No modifications requested**

Motion Approval: **Approved**	**For:** 7	**Against:** 0	**Abstain:** 0	**Recuse:** 0	**Not Present:** 0

Basic Research Amendment #49	**Protocol ID:** IBC 2127	**PI:** Vachharajani	**Biosafety Level:** BSL-2	**NIH Cat.:** N/A

Project Titles:
Immune response in sepsis

Associated Grant Numbers:
R01GM99807

Summary of Approved Items:
Acquisition of samples from healthy and septic patients, MRSA isolates, and Staphylococcus aureus, process cells for analysis; Human-derived materials.

Requested Additions/Changes:

- Room additions

Function/Nature of Recombinant Genes to be Expressed:
☒ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☐ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism ☐ Other

Species of Recombinant Genes to be Expressed:
☒ N/A ☐ Human ☐ Murine ☐ Bacterial ☐ Viral ☐ Other

Risk Assessment Discussion: ☒ Yes ☐ No	**Facilities, Procedures, and Safety Practices Reviewed:** ☒ Yes ☐ No
PI/Supervisor Training (Y/N): ☒ Yes ☐ No	**Handler Training (Y/N):** ☒ Yes ☐ No

Discussion/Required Modifications:
- No modifications requested

Motion Approval:	**For:**	**Against:**	**Abstain:**	**Recuse:**	**Not Present:**
Approved	7	0	0	0	0

IV. Other Business

None